Elevai Labs (ELAB) Competitors

Talphera (NASDAQ:TLPH) and Elevai Labs (NASDAQ:ELAB) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, institutional ownership, dividends, risk, earnings, analyst recommendations, media sentiment, valuation and profitability.

Do analysts recommend TLPH or ELAB?

Talphera currently has a consensus price target of $4.33, indicating a potential upside of 639.48%. Given Talphera's stronger consensus rating and higher possible upside, analysts plainly believe Talphera is more favorable than Elevai Labs.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Talphera	0 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.50
Elevai Labs	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media favor TLPH or ELAB?

In the previous week, Talphera and Talphera both had 4 articles in the media. Elevai Labs' average media sentiment score of 0.37 beat Talphera's score of 0.22 indicating that Elevai Labs is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Talphera	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Elevai Labs	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in TLPH or ELAB?

37.7% of Talphera shares are held by institutional investors. Comparatively, 22.2% of Elevai Labs shares are held by institutional investors. 3.2% of Talphera shares are held by insiders. Comparatively, 0.6% of Elevai Labs shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Which has more risk and volatility, TLPH or ELAB?

Talphera has a beta of 0.2, meaning that its share price is 80% less volatile than the S&P 500. Comparatively, Elevai Labs has a beta of -2.95, meaning that its share price is 395% less volatile than the S&P 500.

Does the MarketBeat Community prefer TLPH or ELAB?

Talphera received 9 more outperform votes than Elevai Labs when rated by MarketBeat users.

Company	Underperform	Outperform
Talphera	Outperform Votes 9 100.00%	Underperform Votes No Votes
Elevai Labs	N/A	N/A

Which has better earnings and valuation, TLPH or ELAB?

Elevai Labs has higher revenue and earnings than Talphera. Talphera is trading at a lower price-to-earnings ratio than Elevai Labs, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Talphera	$281K	35.51	-$18.40M	-$0.69	-0.85
Elevai Labs	$2.45M	1.15	-$4.30M	-$433.87	-0.01

Is TLPH or ELAB more profitable?

Talphera has a net margin of 0.00% compared to Elevai Labs' net margin of -223.41%. Talphera's return on equity of -118.46% beat Elevai Labs' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Talphera	N/A	-118.46%	-65.82%
Elevai Labs	-223.41%	-124.93%	-85.10%

Summary

Talphera beats Elevai Labs on 13 of the 17 factors compared between the two stocks.